Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingRegence Whole-Body DXA Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentRegencePolicy 41

    Whole Body Dual X-Ray Absorptiometry (DXA) to Determine Body Composition

    Customize your policy alerts

    Sign up for regence Policy 41 alerts

    Get alerted when Policy 41 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of whole-body DXA used to measure lean tissue mass and total or regional body fat. Regence considers this service investigational for all indications, subject to applicable contract terms.

    Policy Summary
    PayerRegence
    PolicyWhole Body Dual X-Ray Absorptiometry (DXA) to Determine Body Composition
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewSep 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionExpect claims for whole-body DXA performed to determine body composition to be denied because the service is investigational for all indications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All indicationsCoverage status
    InvestigationalPolicy classification
    3 compartmentsBody-composition assessment
    NoneDedicated billing code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Investigational Coverage Status

    Investigational / Not Covered

    Whole-body DXA to determine body composition is considered investigational for all indications.

    Investigational service: Whole-body dual X-ray absorptiometry (DXA) to determine body composition is considered investigational for all indications.

    No covered indication is identified in this policy.

    Investigational for all indications

    Whole-body DXA to determine body composition is considered investigational for all indications.

    Investigational service: Whole-body dual X-ray absorptiometry (DXA) to determine body composition is investigational for all indications.

    There is not enough research to show that the service improves health outcomes, and no clinical guidelines based on research recommend it.

    Coding Information

    CPT HCPCSCPTExperimental
    76499Unlisted diagnostic radiographic procedure

    Provider and Claims Guidance

    Denial Risk

    Whole-body DXA is investigational for all indications

    Whole-body dual X-ray absorptiometry (DXA) to determine body composition is considered investigational for all indications and is therefore subject to denial under the policy.

    Denial Risk

    Claims are subject to denial

    Claims for whole-body DXA performed to determine body composition are subject to denial because the service is considered investigational for all indications.

    Clinical Background

    Whole-body DXA (also called DEXA) estimates body composition by measuring lean tissue mass and total or regional body fat. The technique can provide a three-compartment assessment of fat mass, lean body mass, and bone mass, including measurements in defined regions such as the arms, legs, and trunk.

    DXA results are estimates based on assumptions about tissue distribution and fat-free-mass hydration. The technique assumes hydration of fat-free mass remains constant at 73%, although reported hydration can vary from 67% to 85% and may vary with disease states. Although whole-body DXA remains widely used in research and has been studied in several clinical conditions, the policy notes that evidence has not established improved health outcomes from its clinical use.

    Terminology

    Whole-body DXA
    TechniqueA whole-body DXA technique used to measure body composition.
    Lean tissueMeasures lean tissue mass.
    Body fatMeasures total and regional body fat.
    DXA/DEXA
    MethodDual-energy X-ray absorptiometry uses X-rays at two energies and analyzes their differential attenuation.
    EstimatesProvides estimates of fat mass, lean body mass, and bone mass.
    Anatomical regionsCan determine body composition in defined regions such as the arms, legs, and trunk.

    Indication Determination

    Determination or monitoring of body composition

    Whole-body DXA used to determine or monitor body composition is not covered under this policy.

    Investigational for all indications: Whole-body DXA used to determine body composition is considered investigational regardless of the clinical indication.

    The policy does not identify a covered indication.

    Determination of body composition

    Whole-body DXA used to determine body composition is not covered under this policy.

    Any indication: Whole-body DXA to determine body composition is considered investigational regardless of the clinical indication.

    Noncovered Services

    Whole-body DXA used for body-composition assessment—including measurement of lean tissue mass, total body fat, or regional body fat—is not covered because it is considered investigational for all indications. The policy does not identify a covered indication, and available research has not shown that the service improves health outcomes or that research-based clinical guidelines recommend its use for determining body composition.

    Policy Summary
    PayerRegence
    PolicyWhole Body Dual X-Ray Absorptiometry (DXA) to Determine Body Composition
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewSep 1, 2026
    Next Review DateJuly 1, 2027
    Key ActionExpect claims for whole-body DXA performed to determine body composition to be denied because the service is investigational for all indications.
    SourceLink
    On This Page
    Investigational Coverage StatusCoding InformationProvider and Claims GuidanceClinical BackgroundTerminologyIndication DeterminationNoncovered Services